Skip to main content

China's DCP Capital Invests In Venus Medtech

Venus Medtech announced that it has entered into a definitive investment agreement with DCP Capital. The investment will be used by Venus Medtech to accelerate the upgrading and internationalization of existing valve products, support the company to rapidly enter into the clinical research stage for its new mitral/tricuspid valve disease treatment technology, and lay a solid foundation for the company to comprehensively enter the international heart valve market. Together with a growing economy and an aging population, the incidence of senile calcific aortic valve disease is on the rise and will soon become the main cause of valvular disease in China. At...